PRESS RELEASES

PRESS RELEASE

Abbott’s ‘Above the Bias’ Film Reveals Misconceptions Can Impact Diabetes Care

‘One cupcake won’t kill you’, ‘I’m going to get diabetes just looking at that’, ‘That person doesn’t look like they have diabetes.’

Abbott's FreeStyle Libre® 2 Now Reimbursed for Children and Adults Living with Diabetes in Alberta

Abbott today announced that the Government of Alberta has added Abbott’s FreeStyle Libre 2* flash glucose monitoring system to the Alberta Drug Benefit List.

New Canadian Report Shows Positivity Instead of Criticism is Key in Diabetes Management

Abbott today released new data highlighting the emotional challenges faced by people living with type 2 diabetes, revealing key motivators to help them manage their condition.

Abbott’s AVEIR™ DR - World's First Dual Chamber Leadless Pacemaker System - Now Available in Canada

Abbott today announced that the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms,1 has been implanted for the first time at the Montreal Heart Institute, in Montreal, Quebec and Foothills Medical Centre in Calgary, Alberta.

Quebec Expands Public Reimbursement of Abbott's FreeStyle Libre® 2 Flash Glucose Monitoring System to More Adults with Diabetes

Abbott today announced that the Government of Quebec’s Régie de l'assurance maladie du Québec (RAMQ) published an update to its formulary that includes expanded reimbursement for Abbott’s FreeStyle Libre 2* flash glucose monitoring system to more adults living with type 1 and type 2 diabetes.

Canadian First - Abbott Advances Chronic Pain Management with the World’s Smallest Implanted, Rechargeable Spinal Cord Stimulation System

Abbott today announced that the company’s Eterna™ SCS system – the smallest implantable, rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain, has been used for the first time in Canada.

Real-World Data Show Abbott’s FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Abbott today announced new data from two real-world studies showing people with Type 2 diabetes using GLP-1 medicines and FreeStyle Libre technology together had greater improvement in their HbA1c when compared to those treated with GLP-1 medicines only.

LifeLabs and Abbott Announce Innovative Collaboration to Support British Columbians Living with Diabetes

LifeLabs, the most trusted brand in health diagnostic services* and Abbott, the global healthcare company, have launched an innovative collaboration to support British Columbians living with diabetes and their healthcare teams.

New Update to Abbott’s FreeStyle Libre 2 App Enables Canadians Using FreeStyle Libre® 2 System to Receive Automatic Glucose Readings Every Minute

Abbott today announced an update to its latest FreeStyle Libre 2 app, which will allow Canadians who use the FreeStyle Libre 2* system to get real-time minute-by-minute glucose readings automatically† displayed on the app.

Canadian First - Abbott’s TactiFlexTM Ablation Catheter Used to Treat AFib

Abbott today announced that the company’s TactiFlex™ Ablation Catheter, Sensor Enabled™, the world’s first ablation catheter with a flexible tip and contact force technology, has been used for the first time in Canada at the Foothills Medical Centre in Calgary, Alberta, to treat atrial fibrillation (AFib).

SHOWING 1 - 8 OF 10

10

8

© 2025 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.